ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 中枢神経・末梢神経の悪性リンパ腫
文献概要
中枢神経系原発悪性リンパ腫（PCNSL）は，脳腫瘍の1〜5％を占めており，CTやMRIなどの従来の画像診断で病変を特定することができる。しかし，グリオーマ，感染症（進行性多巣性白質脳症，トキソプラズマ症），脱髄性疾患（多発性硬化症）などの他の疾患で見られるような非典型的な所見を示す病変の場合，鑑別診断は困難となる。本論では，従来型のCTやMRIとPET-CTを含むadvanced imagingからPCNSLを他の疾患と区別するための画像所見や，予後因子，治療効果，遺伝子変異などの他の特徴を検出するのに役立つ所見を提示する。
参考文献
1）Haldorsen IS, Espeland A, Larsson EM: Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32: 984-992, 2011
2）Haldorsen IS, Kråkenes J, Krossnes BK, Mella O, Espeland A: CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 30: 744-751, 2009
3）Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, et al: MRI features of primary central nervous system lymphomas at presentation. Neurology 57: 393-396, 2001
4）Küker W, Nägele T, Korfel A, Heckl S, Thiel E, et al: Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72: 169-177, 2005
5）Fine HA, Mayer RJ: Primary central nervous system lymphoma. Ann Intern Med 119: 1093-1104, 1993
6）Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S: Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31: 60-66, 2010
7）Ota Y, Naganawa S, Kurokawa R, Bapuraj JR, Capizzano A, et al: Assessment of MR imaging and CT in differentiating hereditary and nonhereditary paragangliomas. AJNR Am J Neuroradiol 42: 1320-1326, 2021
8）Toh CH, Castillo M, Wong AMC, Wei KC, Wong HF, et al: Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 29: 471-475, 2008
9）Ota Y, Liao E, Kurokawa R, Syed F, Baba A, et al: Diffusion-weighted and dynamic contrast-enhanced MRI to assess radiation therapy response for head and neck paragangliomas. J Neuroimaging: 2021 [online ahead of print] ［doi: 10.1111/jon.12875］
10）Ota Y, Capizzano AA, Moritani T, Naganawa S, Kurokawa R, et al: Comprehensive review of Wernicke encephalopathy: pathophysiology, clinical symptoms and imaging findings. Jpn J Radiol 38: 809-820, 2020
11）Toh CH, Wei KC, Chang CN, Ng SH, Wong HF: Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol 34: 1145-1149, 2013
12）Kickingereder P, Sahm F, Wiestler B, Roethke M, Heiland S, et al: Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. AJNR Am J Neuroradiol 35: 1503-1508, 2014
13）Hatzoglou V, Oh JH, Buck O, Lin X, Lee M, et al: Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma. J Neurooncol 140: 351-358, 2018
14）Kim HS, Jahng GH, Ryu CW, Kim SY: Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 30: 1574-1579, 2009
15）Go JL, Lee SC, Kim PE: Imaging of primary central nervous system lymphoma. Neurosurg Focus 21: E4, 2006 ［doi: 10.3171/foc.2006.21.5.5］
16）Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IGH, et al: FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33: 164-168, 2006
17）Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, et al: Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography. J Nucl Med 33: 532-536, 1992
18）Heiss WD: The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 36 (Suppl 1): S105-S112, 2009
掲載誌情報
